Selective cytopheresis devices and related methods thereof
View Patent ↗The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.
1. A method for processing cells contained within a body fluid from a subject with acute renal failure, wherein the cells are primed or activated leukocytes, the method comprising:
(a) sequestering extracorporeally the cells from the subject; and
(b) treating the cells sequestered during step (a) with a calcium chelator to inhibit release of a pro-inflammatory substance from the cells or to deactivate the cells.
2. The method of claim 1 , wherein the cells are sequestered for a time sufficient to inhibit the release of the pro-inflammatory substance from the cells or to deactivate the cells.
3. The method of claim 1 , wherein the cells are sequestered for a prolonged period of time.
4. The method of claim 3 , wherein the cells are sequestered for at least one hour.
5. The method of claim 1 , further comprising the step of returning the cells produced in step (b) back to the subject.
6. The method of claim 1 , wherein the calcium chelator comprises citrate.
7. The method of claim 1 , wherein the calcium chelator ameliorates inflammation associated with the cells.
8. The method of claim 1 , wherein step (a) is performed using a device defining a passageway comprising a region configured to sequester the cells.
9. The method of claim 8 , wherein the calcium chelator is infused into the passageway.
10. The method of claim 9 , wherein the calcium chelator comprises citrate.
11. The method of claim 8 , wherein the region configured to sequester the cells comprises a membrane.
12. The method of claim 11 , wherein the membrane is porous.
13. The method of claim 11 , wherein the membrane has a surface area greater than about 0.2 m 2 .
14. The method of claim 11 , wherein the cells bind to a surface of the membrane.
15. The method of claim 8 , wherein the cells bind to a surface of the region.
16. The method of claim 8 , wherein the region configured to sequester the cells is configured so that shear force within the region is less than about 1000 dynes/cm 2 when fluid passes through the passageway at a rate of from about 100 mL/minute to about 500 mL/minute.
17. The method of claim 16 , wherein the region configured to sequester the cells is configured so that shear force within the region is less than about 100 dynes/cm 2 when fluid passes through the passageway at a rate of from about 100 mL/minute to about 500 mL/minute.
18. The method of claim 17 , wherein step (b) comprises exposing the cells to the calcium chelator for less than an hour.
19. The method of claim 17 , wherein step (b) comprises exposing the cells to the calcium chelator from 1 to 24 hours.
20. The method of claim 1 , wherein step (b) comprises exposing the cells to the calcium chelator for less than an hour.
21. The method of claim 1 , wherein step (b) comprises exposing the cells to the calcium chelator from 1 to 24 hours.
22. A method of treating a subject with acute renal failure, the method comprising:
(a) sequestering extracorporeally primed or activated leukocytes in a body fluid from the subject; and
(b) treating the leukocytes sequestered during step (a) with a calcium chelator to inhibit release of a pro-inflammatory substance from the leukocytes or to deactivate the leukocytes.
23. The method of claim 22 , wherein the calcium chelator ameliorates an inflammatory response associated with the primed or activated leukocytes.
24. The method of claim 23 , wherein the calcium chelator is citrate.
25. The method of claim 22 , wherein the leukocytes are sequestered for a time sufficient to inhibit the release of the pro-inflammatory substance from the leukocytes or to deactivate the leukocytes.
26. The method of claim 22 , wherein the leukocytes are sequestered for a prolonged period of time.
27. The method of claim 26 , wherein the leukocytes are sequestered for at least one hour.
28. The method of claim 22 , further comprising the step of returning the leukocytes produced in step (b) back to the subject.
29. The method of claim 22 , wherein the calcium chelator comprises citrate.
30. The method of claim 22 , wherein step (a) is performed using a device defining a passageway comprising a region configured to sequester the leukocytes.
31. The method of claim 30 , wherein the calcium chelator is infused into the passageway.
32. The method of claim 31 , wherein the calcium chelator comprises citrate.
33. The method of claim 30 , wherein the region configured to sequester the leukocytes comprises a membrane.
34. The method of claim 33 , wherein the membrane is porous.
35. The method of claim 33 , wherein the membrane has a surface area greater than about 0.2 m 2 .
36. The method of claim 33 , wherein the leukocytes bind to a surface of the membrane.
37. The method of claim 30 , wherein the region configured to sequester the leukocytes is configured so that shear force within the region is less than about 1000 dynes/cm 2 when fluid passes through the passageway at a rate of from about 100 mL/minute to about 500 mL/minute.
38. The method of claim 37 , wherein the region configured to sequester the leukocytes is configured so that shear force within the region is less than about 100 dynes/cm 2 when fluid passes through the passageway at a rate of from about 100 mL/minute to about 500 mL/minute.
39. The method of claim 38 , wherein step (b) comprises exposing the leukocytes to the calcium chelator for less than an hour.
40. The method of claim 38 , wherein step (b) comprises exposing the leukocytes to the calcium chelator from 1 to 24 hours.
41. The method of claim 30 , wherein the leukocytes bind to a surface of the region.
42. The method of claim 22 , wherein step (b) comprises exposing the leukocytes to the calcium chelator for less than an hour.
43. The method of claim 22 , wherein step (b) comprises exposing the leukocytes to the calcium chelator from 1 to 24 hours.